The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 13, 2015

Filed:

Mar. 15, 2013
Applicant:

Coda Therapeutics, Inc., San Diego, CA (US);

Inventors:

Anthony Phillips, San Diego, CA (US);

David Eisenbud, San Diego, CA (US);

Scott Bannan, San Diego, CA (US);

David Pool, San Diego, CA (US);

Grove Matsuoka, San Diego, CA (US);

Tracey Sunderland, San Diego, CA (US);

Bradford Duft, San Diego, CA (US);

Assignee:

CoDa Therapeutics, Inc., San Diego, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/113 (2010.01); C07K 14/47 (2006.01); A61B 5/107 (2006.01); A61B 5/11 (2006.01); A61B 5/00 (2006.01); A61K 31/7088 (2006.01); A61K 47/00 (2006.01); A61K 9/00 (2006.01); A61K 48/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/47 (2013.01); A61B 5/1072 (2013.01); A61B 5/1079 (2013.01); A61B 5/1109 (2013.01); A61B 5/445 (2013.01); A61B 5/4848 (2013.01); A61B 5/7275 (2013.01); A61K 9/0014 (2013.01); A61K 31/7088 (2013.01); A61K 47/00 (2013.01); A61K 48/00 (2013.01); C12N 15/1138 (2013.01); C12N 2310/11 (2013.01);
Abstract

This invention concerns improved methods, uses, and kits for treating chronic wounds through the administration of anti-connexin agents, particularly anti-connexin 43 antisense polynucleotides. The methods, uses, and kits of the invention are based on the surprising and unexpected discovery that chronic wounds that do not increase or decrease in size by more than a pre-determined amount during a pre-treatment phase are more amenable to successful treatment than wounds whose size varies outside the target range during the pre-treatment phase.


Find Patent Forward Citations

Loading…